Charles River Laboratories International (CRL) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 27, 2026
- EPS actual
- $3.02
- EPS estimate
- $2.74
- EPS surprise
- +10.13%
- Revenue surprise
- +2.75%
- Revenue
- $1.0B
- Revenue estimate
- $977.2M
- Reported
- Aug 5, 2026
Charles River Laboratories reported Q2 2026 results on August 5, 2026. Earnings per share came in at $3.02, ahead of the $2.74 estimate by 10.13%. Revenue was about $1.0 billion, 2.75% above the $977.2 million consensus. Compared with Q2 2025, EPS fell about 3% from $3.12, while revenue was roughly flat. EPS rose about 47% from Q1's $2.06, the low in the table.
The longer record shows a gradual decline in earnings on steady sales. Annual EPS slipped each year, from $11.13 in 2022 to $10.65 in 2023, $10.32 in 2024 and $10.28 in 2025, a drop of about 8%. Quarterly revenue has held close to $1.0 billion since 2022. The first half of 2026 adds up to $5.08 per share, about 7% below the first half of 2025. Q2 2025 holds the EPS high in the table at $3.12. Charles River beat the EPS estimate in all 20 quarters shown. The largest beat was 24.69% in Q2 2025, and the smallest was 1.16% in Q2 2022.
Charles River reported Q3 results between November 2 and November 8 in each of the past five years. That points to early November 2026 for the next report.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 5, 2026 | $2.74 | $3.02 | +10.13% | $1.0B | SEC |
| Q1 2026 | May 7, 2026 | $1.94 | $2.06 | +6.00% | $995.8M | SEC |
| Q4 2025 | Feb 18, 2026 | $2.34 | $2.39 | +1.98% | $994.2M | SEC |
| Q3 2025 | Nov 5, 2025 | $2.34 | $2.43 | +3.95% | $1.0B | SEC |
| Q2 2025 | Aug 6, 2025 | $2.50 | $3.12 | +24.69% | $1.0B | SEC |
| Q1 2025 | May 7, 2025 | $2.08 | $2.34 | +12.73% | $984.2M | SEC |
| Q4 2024 | Feb 19, 2025 | $2.53 | $2.66 | +5.24% | $1.0B | SEC |
| Q3 2024 | Nov 6, 2024 | $2.42 | $2.59 | +6.91% | $1.0B | SEC |
| Q2 2024 | Aug 7, 2024 | $2.39 | $2.80 | +16.95% | $1.0B | SEC |
| Q1 2024 | May 9, 2024 | $2.06 | $2.27 | +9.93% | $1.0B | SEC |
| Q4 2023 | Feb 14, 2024 | $2.40 | $2.46 | +2.42% | $1.0B | SEC |
| Q3 2023 | Nov 8, 2023 | $2.36 | $2.72 | +15.40% | $1.0B | SEC |
| Q2 2023 | Aug 9, 2023 | $2.64 | $2.69 | +1.96% | $1.1B | SEC |
| Q1 2023 | May 11, 2023 | $2.59 | $2.78 | +7.40% | $1.0B | SEC |
| Q4 2022 | Feb 22, 2023 | $2.75 | $2.98 | +8.55% | $1.1B | SEC |
| Q3 2022 | Nov 2, 2022 | $2.50 | $2.63 | +5.09% | $989.2M | — |
| Q2 2022 | Aug 3, 2022 | $2.74 | $2.77 | +1.16% | $973.1M | — |
| Q1 2022 | May 4, 2022 | $2.72 | $2.75 | +1.18% | $913.9M | — |
| Q4 2021 | Feb 16, 2022 | $2.43 | $2.49 | +2.38% | $905.0M | — |
| Q3 2021 | Nov 3, 2021 | $2.58 | $2.70 | +4.48% | $895.9M | — |
Quarterly revenue
Frequently asked questions
When did Charles River Laboratories International (CRL) last report earnings?
Charles River Laboratories International last reported on Aug 5, 2026, covering fiscal Q2 2026.
Did CRL beat earnings estimates?
Yes. Charles River Laboratories International reported EPS of $3.02 for Q2 2026 against a $2.74 estimate — a 10.13% beat.
How much revenue did CRL report last quarter?
Charles River Laboratories International reported $1.0B in revenue for Q2 2026, against a consensus estimate of $977.2M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.